<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The failure of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> treatments is partly due to overexpression of CXCR4 by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, which plays a critical role in cell <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Moreover, serum alkaline phosphatase (ALP) levels are frequently elevated in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>A <z:chebi fb="5" ids="18154">polysaccharide</z:chebi>, <z:chebi fb="0" ids="52071">dextran</z:chebi>, was chosen as the vector of siRNA </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="15746">Spermine</z:chebi> was conjugated to oxidized <z:chebi fb="0" ids="52071">dextran</z:chebi> by reductive amination process to obtain cationized <z:chebi fb="0" ids="52071">dextran</z:chebi>, so-called <z:chebi fb="0" ids="52071">dextran</z:chebi>-<z:chebi fb="0" ids="15746">spermine</z:chebi>, in order to prepare CXCR4-siRNAs/<z:chebi fb="0" ids="52071">dextran</z:chebi>-<z:chebi fb="0" ids="15746">spermine</z:chebi> nanoparticles </plain></SENT>
<SENT sid="4" pm="."><plain>The fabricated nanoparticles were used in order to investigate whether downregulation of CXCR4 expression could affect serum ALP in mouse models of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> was established in BALB/C mice following injection of mouse colon <z:mp ids='MP_0002038'>carcinoma</z:mp> cells CT.26WT through the tail vein </plain></SENT>
<SENT sid="6" pm="."><plain>CXCR4 siRNA for two sites of the target gene was administered following injection of naked siRNA or siRNA encapsulated into nanoparticles </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In vivo animal data revealed that CXCR4 silencing by <z:chebi fb="0" ids="52071">dextran</z:chebi>-<z:chebi fb="0" ids="15746">spermine</z:chebi> nanoparticles significantly downregulated CXCR4 expression compared with naked CXCR4 siRNA </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, there was correlation between CXCR4 expression and serum ALP </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: CXCR4 siRNA/<z:chebi fb="0" ids="52071">dextran</z:chebi>-<z:chebi fb="0" ids="15746">spermine</z:chebi> nanoparticles appear to be highly effective, and may be suitable for further in vivo applications </plain></SENT>
<SENT sid="10" pm="."><plain>Further research evaluation will be needed to determine the effect of CXCR4 silencing on serum ALP levels, which may be a useful marker to predict <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>